Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Urine-Based Assay Diagnoses Common Lung Infection in Immunocompromised People

By LabMedica International staff writers
Posted on 08 Aug 2025

Invasive Aspergillosis (IA), a life-threatening fungal infection, poses a serious threat to immunocompromised individuals, especially those with hematologic malignancies, transplants, or severe lung diseases. More...

Traditional IA diagnostic methods are invasive, costly, and slow, with limited sensitivity—often forcing clinicians to rely on broad-spectrum antifungal treatments. Global health agencies, including the WHO, have called for better diagnostic tools as drug resistance and toxicity rise. Now, a groundbreaking urine assay offers a non-invasive diagnostic approach for detecting IA

Pearl Diagnostics’ (Baltimore, MD, USA) MycoMEIA Aspergillus Assay is intended for aiding the diagnosis of IA. The test uses a microplate-based enzyme-linked immunoassay (ELISA) to detect biomarkers of the infection through a non-invasive urine sample. The assay leverages proprietary Smart Antibody technology to identify microbial extracellular vesicles.

The MycoMEIA assay underwent clinical validation at U.S. and European centers. Results showed that it offers higher sensitivity than current tests and can detect the disease earlier in its progression. With a sensitivity of approximately 90%, the tool also provides a strong negative predictive value—enabling clinicians to rule out IA confidently and avoid unnecessary treatments.

The MycoMEIA assay could lead to major improvements in care for at-risk patients, offering earlier intervention and reducing the toxic side effects from unnecessary antifungal use. The assay’s ability to reduce unnecessary medication use could also improve antifungal stewardship. The FDA has granted 510(k) clearance to the MycoMEIA assay, making it the first urine-based assay to receive FDA clearance as an aid to diagnose IA. The assay also carries a CE mark, indicating its potential for use in global clinical settings.

"The high negative predictive value of this assay should empower clinicians to withhold unnecessary antifungal therapies in severely ill patients," said Dr. Johan Maertens, Professor and Physician of Hematology, University Hospital Leuven. “Meanwhile, its sensitivity approximating 90% provides an excellent, non-invasive, and timely tool to diagnose invasive aspergillosis, the most common mold infection, in at-risk patients suspected of having this fungal disease.”

Related Links:
Pearl Diagnostics 


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Slide Scanner System
NanoZoomer S540MD
Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

AI in Cancer Diagnosis and Molecular Testing Takes Center Stage at AMP 2026

Artificial intelligence (AI) is increasingly being integrated into molecular diagnostics, offering new approaches to interpreting complex genetic information, classifying cancers, and optimizing laboratory testing.... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Pathology

view channel
Image Credit: Adobe Stock

New Training Approach Helps AI Distinguish Neighboring Cells in Tissue

Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.